Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


12345678910111213...2425»
  • ||||||||||  Clinical, Review, Journal:  Rituximab for people with multiple sclerosis. (Pubmed Central) -  Mar 12, 2025   
    There is an increased risk of serious (hospital-treated) infections with rituximab compared with other DMTs, although the absolute risk is low. High-quality (prospectively registered) NRSIs should be conducted to draw more reliable conclusions about the potential benefits and harms of rituximab in people with MS.
  • ||||||||||  Review, Journal:  Comorbidities of hypothyroidism. (Pubmed Central) -  Mar 11, 2025   
    Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Enrollment closed, Trial completion date, Trial primary completion date:  TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) -  Feb 18, 2025   
    P=N/A,  N=900, Active, not recruiting, 
    Increased awareness of this possible side effect, and prolonged monitoring, is warranted. Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Equine Anti-Thymocyte Globulin and Alemtuzumab Are Associated with the Highest Survival Among Common Induction Therapies in U.S. Lung Transplant Recipients (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1898;    
    While rejection / respiratory failure-related deaths were lowest with alemtuzumab (HR=0.75 [0.63-0.90], p=0.002), cancer-related deaths were increased (HR=1.39 [1.08-1.78], p=0.009), versus no induction.Conclusion Using Equine ATG or alemtuzumab as induction therapy may increase survival in lung transplant recipients, largely mediated by reduced rejection-related deaths. Use of these agents, particularly Equine ATG as it seems most favorable overall, should be considered as an alternative to basiliximab.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Serum Proteomics Analysis of Lung Transplant Patients Receiving Different Induction Therapies (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1268;    
    Additionally, the upregulation of immunoglobulins and MCAM in the ATG group suggests a more pro-inflammatory state. The downregulation of fibulin-1 and fetuin-B, elevated in lung diseases, was notable in alemtuzumab over time and in alemtuzumab versus no-induction therapy, suggesting potential benefits for graft survival compared to no-induction therapy, possibly ATG as well.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Journal:  Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. (Pubmed Central) -  Jan 17, 2025   
    Patients initiating heDMAs (natalizumab, alemtuzumab, and ocrelizumab) or meDMAs (interferon beta-1a, interferon beta-1b, fingolimod, teriflunomide, dimethyl fumarate, and glatiramer acetate) were included...In MS, heDMAs were associated with a greater risk of serious infection and UTI compared with meDMAs. These findings suggest the need to carefully monitor and manage the infection risk to optimize the use of heDMAs in MS.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? (Pubmed Central) -  Dec 10, 2024   
    However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells. (Pubmed Central) -  Dec 1, 2024   
    Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs. Ten participants (3 males, 7 females) had blood samples collected at multiple intervals (Day 0, 1, 5, then weekly for 8
  • ||||||||||  Mayzent (siponimod) / Novartis, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series. (Pubmed Central) -  Sep 12, 2024   
    In conclusion, the long-term management of patients treated with Alemtuzumab transitioning to secondary progressive MS requires a proactive and multidisciplinary approach. By addressing the challenges associated with treatment limitations and short-term monitoring recommendations while considering alternative therapeutic options like Siponimod, clinicians can optimize outcomes and ensure continuity of care for individuals with MS.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Retrospective data, Review, Journal, Immunomodulating:  Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Sep 10, 2024   
    Given the relative rarity of PMS, controlled, non-randomised studies on large samples may usefully integrate data from pivotal RCTs. Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Riesgo de c (Pubmed Central) -  Sep 3, 2024   
    Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Risk of skin cancer associated with disease-modifying therapies in multiple sclerosis: a modern comprehensive evidence review. (Pubmed Central) -  Sep 3, 2024   
    Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Biomarker, Journal:  Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. (Pubmed Central) -  Sep 3, 2024   
    During the follow-up period, no changes were identified in the sGFAP values. Alemtuzumab leads to the normalization of sNfL values in MS patients after 2 years of treatment, with no apparent effect on sGFAP values.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021. (Pubmed Central) -  Aug 31, 2024   
    We divided the total number of monthly prescriptions by 12 or 2 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates...In line with global trends, MS prevalence is escalating in Australia, particularly in higher-latitude states. MS prevention is crucial to halt this disturbing trend.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Journal:  Safety and effectiveness of disease-modifying therapies after switching from natalizumab. (Pubmed Central) -  Jul 30, 2024   
    Mean drug survival favored rituximab/ocrelizumab or alemtuzumab over fingolimod (p < 0.001). Our study shows superior effectiveness of rituximab/ocrelizumab and alemtuzumab compared with fingolimod in stable patients switching from NTZ due to JC virus antibody positivity.